NCT06146985View on ClinicalTrials.gov

Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

November 15, 2024

Study Completion Date

May 1, 2025

Conditions

Thyroid Cancer

Interventions

COMBINATION_PRODUCT

20 mg Famitinib & 1200 mg Adebrelimab

Famitinib is a novel multi-targeted tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. Adebrelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to human PD-L1

All Listed Sponsors

lead

Ruijin Hospital

OTHER

NCT06146985 - Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer | Biotech Hunter | Biotech Hunter